InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,344.39
(
0.00%
)
US TECH 100
18,110.40
(
0.31%
)
Dow Jones
39,357.01
(
0.00%
)
Brent Oil
81.29
(
-0.39%
)
Bitcoin
58,950.76
(
-0.68%
)
Post# of 252864
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 835
Posts 120262
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 137112

Friday, 02/17/2012 4:26:45 PM

Friday, February 17, 2012 4:26:45 PM

Post# of 252864
The Copaxone language in Teva’s 20-F filing is somewhat different from the bluster you hear from executives on investor presentations. The 20-F says:

http://www.sec.gov/Archives/edgar/data/818686/000119312512067417/d300203d20f.htm

…our patents on Copaxone have been challenged, and we may face generic competition prior to 2014, when the U.S. Orange Book patents covering Copaxone would otherwise expire.

On investor CC’s, Teva’s executives say that there’s no chance in hell this can occur.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up